CGIX stock forecast
Our latest prediction for Cancer Genetics, Inc.'s stock price was made on the Dec. 15, 2017 when the stock price was at 1.95$.
In the short term (2weeks), CGIX's stock price should outperform the market by 6.13%. During that period the price should oscillate between -7.95% and +18.06%.
In the medium term (3months), CGIX's stock price should outperform the market by 10.90%. During that period the price should oscillate between -18.58% and +48.50%.Get email alerts
Create a solid portfolio with CGIX
About Cancer Genetics, Inc.
Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus: NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.
At the moment the company generates 28M USD in revenues.
On its last earning announcement, the company reported a loss of -0.97$ per share.
The book value per share is 0.62$
Three months stock forecastDec. 15, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|